A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 High-dose in Healthy Volunteers Under Fasting Conditions
Latest Information Update: 05 May 2023
At a glance
- Drugs CKD 385 (Primary)
- Indications Cardiovascular disorders
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
- 01 Jun 2021 New trial record